David Schenkein will step down from Agios Phar­ma­ceu­ti­cals ’ board of di­rec­tors at the end of the month “to de­vote more ...

Bristol Myers Squibb's Opdualag (relatlimab/Opdivo) fails Phase 3 melanoma trial, adding to mixed results for LAG-3/PD-1 targeting immunotherapies.

Moderna is working on restoring investors' faith that its Covid-19 vaccine was not a one-hit-wonder. It also has to show it ...

A series of actions by President Donald Trump's administration have provoked profound anxiety among academic labs that ...

Knownwell expands with 6 new Chicago locations, adding to existing Boston and Dallas clinics. CEO reports 78% virtual visits.

The Senate on Thursday confirmed Robert F. Kennedy Jr. as secretary of Health and Human Services, putting a longtime ...

Agios' Pyrukynd met primary endpoint in Phase 3 study for children with PK deficiency who don't need regular transfusions, ...

Idorsia’s plan to hand over the global rights to its blood pressure drug Tryvio has ended in disappointment after a deal announced in November fell through.

In a surprise move Thursday, Neumora remade its executive team and brought back its former CEO, following last month's ...

Sanofi faces $250M charge after E. coli vaccine developed with J&J fails Phase 3 trial; study ends early due to insufficient ...

Aardvark Therapeutics will debut on Nasdaq at $16/share, to raise $94M for hunger-focused metabolic disease treatments. ARD-101 Phase 3 data expected early 2025.

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, ...